-
2023-506707-25-00
5
2024-04-09
Choroidal neovascularization secondary to pathologic myopia
-
2023-504678-39-00
4
2024-03-13
Heart Failure
-
2022-502584-38-00
5
2023-12-12
Locally advanced squamous cell carcinoma of the head and neck
-
2023-503893-19-00
5
2023-12-06
HIV-1 infection
-
2023-504673-20-00
4
2023-12-06
Ulcerative Colitis
-
2023-503336-41-00
4
2023-11-29
Prophylaxis of Renal Allograft Rejection
-
2022-501418-69-00
5
2023-11-21
Acute Coronary Syndrome
-
2023-503737-22-00
4
2023-11-08
Nonsegmental vitiligo with genital involvement
-
2022-502227-22-00
4
2023-10-25
Autoimmune disease
-
2022-502174-16-00
5
2023-09-13
Macular edema secondary to retinal vein occlusion
-
2022-502546-26-00
3
2023-09-11
Sickle Cell Disease
-
2022-503071-28-00
5
2023-08-31
Squamous Non-small cell Lung Cancer
-
2022-500535-36-01
5
2023-06-12
Moderately to severely active ulcerative colitis
-
2023-506824-96-00
4
2023-05-23
The present study will include a population of patients with establish
-
2024-515018-42-00
4
2023-01-11
Patients treated with lithium carbonate for a bipolar disorder treated
-
2024-511713-38-00
4
2022-12-30
Cisplatine induced hearing loss
-
2024-515185-13-00
5
2022-12-21
geographic atrophy
-
2023-503794-38-00
5
2022-11-24
Prevention of stroke or systemic embolism in atrial fibrillation
-
2023-507430-25-00
1
2022-10-03
Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and
-
2023-503615-14-00
4
2022-09-29
Relapsed or Refractory Classical Hodgkin Lymphoma
-
2024-513559-34-00
5
2022-07-19
Small Cell Lung Cancer (SCLC)
-
2024-514347-28-00
5
2022-06-02
Men and women over 18 years of age with renal failure renal failure st
-
2024-513653-75-00
5
2022-05-30
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called
-
2024-513173-44-00
4
2022-05-03
Adults patients having non severe HLH